SantosACLandMGPLimaEC.Ammonia level as a proxy of asparaginase inactivation in children: a strategy for classification of infusion reactions. J Oncol Pharm Pract2021;
0: 1–9. https://doi.org/10.1177%2F1078155221998738
2.
KloosRQHUyl-de GrootCAvan LitsenburgRR, et al.
A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer2017;
64: e26651.
3.
BaruchelABrownPRizzariC, et al.
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.ESMO Open2020;
5: e000977.
4.
CecconeloDKMagalhãesMRWerlangICR, et al.
Asparaginase: an old drug with new questions.Hematol Transfus Cell Ther2020;
42: 275–282.
5.
SantosACLandMGPSilvaNP, et al.
Reactions related to asparaginase infusion in a 10-year retrospective.Cohort Rev Bras Hematol Hemoter2017;
39: 337–342.
6.
TongWHvan der SluisIMPietersR.Ammonia levels should not be used as a surrogate marker of levels of asparaginase activity in acute lymphoblastic leukemia patients [Letter to Editor]. Pediatr Blood Cancer2015; 63: 561--562.
7.
CzogałaMBalwierzWSztefkoK, et al.
Utility of ammonia concentration as a diagnostic test in monitoring of the treatment with l-asparaginase in children with acute lymphoblastic leukemia. Biomed Res Int2014;
2014: 1–6.
